Control Peptide for S8500-03J (antiserum) and S8500-03K (affinity purified) 21-aa peptide from human Survivin . The inhibitors of apoptosis proteins (IAPs) are a widely expressed gene family of apoptotic inhibitors. The central mechanisms of IAP apoptotic suppression appear to be through direct caspases and pro-caspase inhibition. Recently, a new human gene encoding a structurally and unique IAP designated Survivin has been identified. Survivin (human 142 aa, ~16.5kD, chromosome 17q25, Mouse TIAP/Survivin 140 aa) contains a single baculovirus IAP repeat and lacks a C-terminal RING finger. An isoform of survivin, Beta-form, that has a 23-aa insertion in the BIR-domain has been reported. Mouse survivin is also shown to be alternatively spliced into 3 forms: Long 140-aa, 121-aa (missing the oiled-coil domain), and 40-aa form (missing the IAP repeat and coiled domain). Survivin140 and 121-aa inhibits caspase-3 activity. Human survivin has the property of oncofetal antigens: highly expressed in less-differentiated embryonic cells or rapidly dividing tumor cell but not in fully differentiated adult tissues. Elevated levels of Survivin are found in human fetal lung, liver, heart, kidney, and gastrointestinal tract. In mouse embryonic tissues, Survivin is detected in most tissues. High level of Survivin was found in most common human cancer, including cancers of the lung, colon, pancreas, prostate, and breast. Expression of Survivin also correlated with the presence of both p53 and bcl-2. Applications: Suitable for use in ELISA and Antibody Blocking. Not suitable for use in Western Blot due to low molecular weight. Other applications not tested. Recommended Dilution: ELISA: 50-100ng control peptide/well. Antibody Blocking: 5-10ug per 1ug S8500-03K (affinity purified antibody) or per 1ul S8500-03J (antiserum). Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4C for short-term only. For long-term storage, store at -20C. Aliquots are stable for at least 6 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
